Document is current
Any future updates will be listed below
-
Authors
Amberg, Bettina https://orcid.org/0000-0002-4526-3897
Köchl, Fabian
Kumpesa, Nadine https://orcid.org/0009-0005-9081-7237
Prasad, Megana
Bochner, Filip
Hernández-Obiols, Mar
Otteneder, Michael B. https://orcid.org/0000-0003-2318-4749
Stalder, Lucas
Shaffo, Frances
Nowrouzi, Ali
Markusic, David
Haegel, Hélène https://orcid.org/0000-0003-4792-4000
Xicluna, Rebecca
Sultan, Marc
Jacobsen, Björn https://orcid.org/0000-0003-0782-6190
Rottenberg, Sven
Valdeolivas, Alberto
Schwalie, Petra C. https://orcid.org/0000-0002-6004-8095
Hahn, Kerstin
- License Information
-
More Information
Article History
Received: 16 April 2025
Revised: 4 February 2026
Accepted: 17 February 2026
First Online: 11 March 2026
Competing interests
: BA, FK, MP, MH, and FS are employees of F Hoffmann-La Roche Ltd. NK, MBO, HH, RX, MS, BJ, AV, PCS, and KH are shareholders of F Hoffmann-La Roche Ltd. AN is an employee and shareholder of Spark Therapeutics Inc., a subsidiary of Roche. DM is an employee of Spark Therapeutics Inc. All other authors declare no competing interests.
: During the preparation of this work, the authors used ChatGPT in order to improve language and readability. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
